CurrentBlue Cross Blue Shield - MassachusettsPolicy 140

Radiofrequency volumetric tissue reduction for internal nasal valve collapse

This policy addresses use of low‑energy, temperature‑controlled radiofrequency treatment (RFVTR) for nasal obstruction due to internal nasal valve collapse and defines coverage stance for Blue Cross Blue Shield of Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyRadiofrequency volumetric tissue reduction for internal nasal valve collapse

Policy CodePolicy 140

Change TypeCode transfer and literature update

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification/preauthorization for inpatient procedures; outpatient RFVTR is not a covered service for specified commercial and Medicare products.

SourceLink

POLICY UPDATE CHANGES

Code 30469 removed from MP 400 and transferred to new MP 140.

Policy updated with literature review through December 18, 2025; references added.

1Investigational CPT codes

24Uncontrolled follow-up (months)

2026-02Last update

21References

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Policy Stance

Investigational / Not Covered Criteria

Covered when ALL of the following are met:

Policy stance: Radiofrequency volumetric tissue reduction (RFVTR) for nasal obstruction due to internal nasal valve collapse is considered investigational.

Applies to Commercial Members (Managed Care HMO and POS, PPO, Indemnity) and Medicare HMO Blue and Medicare PPO Blue as specified.

Outpatient coverage: Outpatient RFVTR is not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue.

See authorization section for precertification requirements for inpatient procedures; inclusion of a code does not guarantee coverage and member contract benefits apply.

Rationale / evidence summary: Evidence from systematic reviews and a randomized controlled trial with 12‑month and 24‑month uncontrolled follow‑up shows some improvements in nasal obstruction scores and a short‑term (3 month) randomized benefit, but limitations (small trial size, limited diversity, short randomized follow‑up, confounding from concurrent medication or nasal dilator use, and treatment restricted to lateral nasal wall repair) leave the overall evidence insufficient to conclude an improvement in net health outcome.

Additional larger, longer, and comparative trials are needed to establish efficacy.

Outpatient radiofrequency volumetric tissue reduction (RFVTR) for nasal obstruction due to internal nasal valve collapse is not a covered service for the product lines listed in this policy. Specifically, outpatient RFVTR is not covered for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM. Providers should note that inclusion of a code in the policy does not guarantee coverage; member contract benefits in effect at the time of service determine coverage and reimbursement.

The policy includes reference sections and a bibliography listing systematic reviews and randomized trials but does not provide additional explicit product-specific exclusions beyond those stated for outpatient RFVTR in the coverage section.

Radiofrequency volumetric tissue reduction for internal nasal valve collapse is designated as investigational. The evidence base includes systematic reviews and a randomized controlled trial with up to 24 months of uncontrolled crossover follow-up, but limitations — including small trial size, limited diversity, short controlled follow-up, and potential confounding from concurrent medication or nasal dilator use — mean the evidence is insufficient to demonstrate an improvement in net health outcome. Additional larger, longer, and comparative trials are needed to confirm efficacy.

No explicit statements labeling RFVTR as not medically necessary are present in the referenced sections; the policy instead classifies the procedure as investigational based on the current evidence.

Provider Actions, Prior Authorization, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization (precertification) is required when the procedure is performed inpatient for all products. For outpatient procedures, radiofrequency treatment of the internal nasal valve (RFVTR) is not covered for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue.

Inpatient procedures: precertification/preauthorization IS REQUIRED for all products.
Outpatient procedures: RFVTR is not a covered service for Managed Care (HMO and POS), PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue.

Documentation Required

Coding and Documentation Guidance

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable. Inclusion or exclusion of a code in this policy does not imply member coverage or provider reimbursement; verify member contract benefits at time of service.

Report services with current CPT/HCPCS/ICD-10 codes and applicable modifiers.
Inclusion of codes in the policy is informational only and not a coverage guarantee.

Step Therapy

Treatment Context (no formal step therapy)

Treatment options include non-surgical measures (external adhesive nasal strips, internal nasal dilators/cones, other lateral wall supports) and surgical interventions (grafting with autograft, allograft, or synthetic materials). There is no formal step therapy requirement described in the source material.

Non-surgical: adhesive strips, nasal dilators/cones, internal lateral wall supports (modified Cottle principle).
Surgical: cartilage grafting (septal or auricular) or allograft/synthetic grafts for severe nasal valve deformity.
Policy notes no formal step therapy is required.

Note

References — Provider Action Note

Reference list provided for clinician review; these reference-only sections do not establish prior authorization criteria, authorization workflows, or denial thresholds. Include these as supporting literature but not as operational authorization rules.

References are for background and do not specify prior authorization or denial criteria.
No explicit authorization or denial criteria are present in the listed references.

Background and Clinical Context

Nasal obstruction is a symptom characterized by subjectively reduced airflow and may result from internal or external nasal valve collapse. The internal nasal valve is the narrowest portion of the nasal airway and contributes substantially to inspiratory resistance; collapse typically results from weakened or damaged lateral nasal cartilage and produces symptomatic congestion and airflow limitation. Clinical assessment often includes maneuvers (for example, lateral support or the Cottle maneuver) to confirm whether nasal valve dysfunction contributes to the patient’s symptoms. Treatment options range from conservative measures (nasal dilators, strips) to surgical approaches (cartilage grafting), and RFVTR has been proposed as a less invasive, in‑office technique to reshape lateral wall tissue with the goal of improving airflow and symptoms.

Definitions and Clinical Examination

Nasal obstruction / Nasal valve collapse

DefinitionNasal obstruction: patient-reported sensation of reduced or insufficient airflow through the nose (eg, congestion or stuffiness)

Internal nasal valve collapse (NVC)Narrowing at the internal nasal valve due to weakened or damaged lateral nasal cartilage leading to increased airflow resistance and symptomatic congestion

Clinical relevanceThe internal nasal valve is the narrowest part of the nasal airway and accounts for at least half of nasal airway resistance; minor further narrowing can produce symptomatic obstruction

Cottle maneuver / modified Cottle

Cottle maneuverClinician (or patient) gently pulls the cheek laterally; subjective improvement in inspiration suggests widening of a collapsed nasal valve

Modified Cottle maneuverClinician inserts a cotton swab or curette into the nasal cavity to support the nasal cartilage; patient reports symptom improvement with inspiration

PurposeBoth maneuvers assess for symptomatic improvement with lateral/internal support and help confirm diagnosis of nasal valve collapse

Temperature-controlled radiofrequency

DefinitionTemperature-controlled radiofrequency (RFVTR): a low-energy, temperature-controlled radiofrequency device treatment performed in-office to remodel subcutaneous/submucosal lateral nasal wall tissue for nasal valve obstruction

Study typesEvaluated in randomized controlled trials (including a sham-controlled RCT) and multiple prospective, multicenter studies

Outcomes evaluatedSymptoms, disease status change, treatment-related morbidity, functional outcomes, and quality of life in RCTs and long-term follow-up studies

OpenPayer

Radiofrequency volumetric tissue reduction for internal nasal valve collapse

Coverage Criteria and Policy Stance

Coding and Study Metrics

Provider Actions, Prior Authorization, and Billing Guidance

Background and Clinical Context

Definitions and Clinical Examination